metaEvidence - study list

meta|evidence oncology

Living systematic review and meta-analysis

metastatic/advanced RCC (mRCC) - 1st line (L1) 11
mRCC - L1 - PDL1 negative 1
mRCC - L1 - PDL1 positive 4

All treatments
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
avelumab based treatment
avelumab plus axitinib

versus all
vs VEGF(R) inhibitor
vs sunitinib

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results

delta: difference in rate or median (if available)

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open